• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe cutaneous reaction with initiation of dupilumab for atopic dermatitis and prurigo nodularis: An unusual adverse effect.

作者信息

Lavin Leore, Chefitz Gabriella, Patel Deep, Baek Woong Kee, Khattri Saakshi

机构信息

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

Department of Pathology, Mount Sinai Morningside/West, New York, New York.

出版信息

JAAD Case Rep. 2024 Apr 23;49:40-43. doi: 10.1016/j.jdcr.2024.04.023. eCollection 2024 Jul.

DOI:10.1016/j.jdcr.2024.04.023
PMID:38883166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11176603/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa3/11176603/2a9a558b4df4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa3/11176603/9be6da5d7190/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa3/11176603/227ca425a6c2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa3/11176603/2a9a558b4df4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa3/11176603/9be6da5d7190/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa3/11176603/227ca425a6c2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa3/11176603/2a9a558b4df4/gr3.jpg

相似文献

1
Severe cutaneous reaction with initiation of dupilumab for atopic dermatitis and prurigo nodularis: An unusual adverse effect.使用度普利尤单抗治疗特应性皮炎和结节性痒疹时出现的严重皮肤反应：一种不寻常的不良反应。
JAAD Case Rep. 2024 Apr 23;49:40-43. doi: 10.1016/j.jdcr.2024.04.023. eCollection 2024 Jul.
2
Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.结节性痒疹中使用度普利尤单抗：当前证据的系统评价及应答预测因素分析。
J Dermatolog Treat. 2022 May;33(3):1547-1553. doi: 10.1080/09546634.2020.1853024. Epub 2020 Dec 3.
3
Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series.度普利尤单抗治疗难治性结节性痒疹的病例系列研究
Cureus. 2020 Jun 21;12(6):e8737. doi: 10.7759/cureus.8737.
4
Dupilumab for prurigo nodularis: Case series and review of the literature.度普利尤单抗治疗结节性痒疹：病例系列及文献综述
Dermatol Ther. 2020 Mar;33(2):e13222. doi: 10.1111/dth.13222. Epub 2020 Jan 16.
5
The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.中文译文：在中国 45 例难治性结节性痒疹患者中，度普利尤单抗治疗的有效性和安全性：一项真实世界观察研究。
J Dermatol. 2023 Aug;50(8):1084-1087. doi: 10.1111/1346-8138.16803. Epub 2023 Apr 23.
6
Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy.度普利尤单抗治疗特应性皮炎伴结节性痒疹样皮损：疗效观察。
J Dermatolog Treat. 2021 Jun;32(4):453-454. doi: 10.1080/09546634.2019.1659479. Epub 2019 Sep 2.
7
[THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS].三例患有难治性结节性痒疹的特应性皮炎儿童
Arerugi. 2020;69(3):213-217. doi: 10.15036/arerugi.69.213.
8
Recalcitrant prurigo nodularis treated successfully with dupilumab.度普利尤单抗成功治疗顽固性结节性痒疹。
JAAD Case Rep. 2019 May 8;5(5):471-473. doi: 10.1016/j.jdcr.2019.03.016. eCollection 2019 May.
9
Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.尼莫利珠单抗：一种创新性的生物制剂，用于控制白细胞介素 31，这是特应性皮炎和结节性痒疹的关键介质。
Actas Dermosifiliogr. 2022 Jul-Aug;113(7):674-684. doi: 10.1016/j.ad.2021.12.014. Epub 2021 Dec 23.
10
A critical review of dupilumab for adult patients with prurigo nodularis.度普利尤单抗治疗成年结节性痒疹患者的批判性综述。
Expert Rev Clin Immunol. 2024 Mar;20(3):249-254. doi: 10.1080/1744666X.2023.2268291. Epub 2023 Oct 12.

引用本文的文献

1
Successful Treatment of Pediatric Atopic Prurigo Nodularis with Dupilumab.度普利尤单抗成功治疗儿童结节性特应性痒疹
Clin Cosmet Investig Dermatol. 2025 Jun 26;18:1609-1613. doi: 10.2147/CCID.S523134. eCollection 2025.

本文引用的文献

1
Incidental improvement of programmed cell death-1 receptor inhibitor-induced vitiligo after initiation of dupilumab therapy for refractory pruritus.在开始使用度普利尤单抗治疗难治性瘙痒后，程序性细胞死亡-1受体抑制剂诱导的白癜风出现意外改善。
JAAD Case Rep. 2023 Sep 26;42:31-34. doi: 10.1016/j.jdcr.2023.09.006. eCollection 2023 Dec.
2
Toxic Epidermal Necrolysis in a Critically Ill African American Woman: A Case Report Written With ChatGPT Assistance.一名危重症非裔美国女性的中毒性表皮坏死松解症：一篇在ChatGPT辅助下撰写的病例报告
Cureus. 2023 Mar 3;15(3):e35742. doi: 10.7759/cureus.35742. eCollection 2023 Mar.
3
Dupilumab for the treatment of prurigo nodularis: A systematic review.
度普利尤单抗治疗结节性痒疹的系统评价。
Front Immunol. 2023 Jan 20;14:1092685. doi: 10.3389/fimmu.2023.1092685. eCollection 2023.
4
Erythema multiforme-like drug eruption associated with dupilumab treatment: Report of an unusual case.与度普利尤单抗治疗相关的多形红斑样药物疹：1例罕见病例报告。
Dermatol Ther. 2022 Nov;35(11):e15792. doi: 10.1111/dth.15792. Epub 2022 Sep 11.
5
Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases.治疗过敏疾病时的度普利尤单抗相关不良事件。
Clin Rev Allergy Immunol. 2022 Jun;62(3):519-533. doi: 10.1007/s12016-022-08934-0. Epub 2022 Mar 11.
6
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供长达 3 年的良好安全性和持续疗效。
Am J Clin Dermatol. 2020 Aug;21(4):567-577. doi: 10.1007/s40257-020-00527-x.
7
Cutaneous Manifestations of Reactions to Biologics.生物制剂反应的皮肤表现。
Curr Allergy Asthma Rep. 2018 Feb 21;18(2):12. doi: 10.1007/s11882-018-0764-z.
8
Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis.多形红斑、史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症：冰冻切片诊断。
J Dermatol. 2010 May;37(5):407-12. doi: 10.1111/j.1346-8138.2009.00746.x.